References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–548.
- SEER. National Cancer Institute – surveillance, epidemiology, and end results – cancer stat facts: lung and bronchus cancer; 2020; [cited 2020 May 4]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
- Travis WD, Asamura H, Bankier AA, et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(8):1204–1223.
- Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260.
- Drilon A, Cappuzzo F, Ou SI, et al. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2017;12(1):15–26.
- Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596–609.
- Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546.
- Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–1502.
- Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet. 2016;387(10026):1354–1356.
- Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943.
- Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957.
- Cai B, Zhou ZY, Xue W, et al. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. J Med Econ. 2021;24(1):131–139.
- Pfizer. Highlights of prescribing information: XALKORI® (crizotinib) capsules, for oral use. US Food and Drug Administration; 2011; [cited 2021 May 14]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=676
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer, version 4; 2021; [updated 2021 Mar 3]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
- ClinicalTrials.gov. CABozantinib in non-small cell lung cancer (NSCLC) patients with MET deregulation (CABinMET); 2019; [cited 2021 Jun 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03911193
- Klempner SJ, Borghei A, Hakimian B, et al. Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases. J Thorac Oncol. 2017;12(1):152–156.
- Wang SXY, Zhang BM, Wakelee HA, et al. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anticancer Drugs. 2019;30(5):537–541.
- US Food and Drug Administration. FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer; 2020; [cited 2021 Mar 2]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
- Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019;19(1):214.
- Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017;143(5):783–791.
- Runyan A, Banks J, Bruni DS. Current and future oncology management in the United States. J Manag Care Spec Pharm. 2019;25(2):272–281.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14.
- Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667–677.
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health. 2007;10(5):336–347.
- America's Health Insurance Plans. Medicare advantage demographics report, 2016; 2019; [cited 2020 Jun 22]. Available from: https://www.ahip.org/wp-content/uploads/MA_Demographics_Report_2019.pdf
- Drilon A, Clark J, Weiss J, et al. OA12.02 updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):S348.
- Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120(Suppl. 23):3781–3792.
- EMD Serono. Flatiron health EHR-derived deidentified database, data on file; 2020.
- EMD Serono. Data on file; 2020.
- VanderLaan PA, Roy-Chowdhuri S. Current and future trends in non-small cell lung cancer biomarker testing: the American experience. Cancer Cytopathol. 2020;128(9):629–636.
- IBM. Micromedex® RED BOOK®; 2021. Available from: www.ibm.com
- Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016;34(11):1111–1131.
- Centers for Medicare & Medicaid Services. Medicare HO: CMS.gov. Hospital outpatient PPS payment by HCPCS code for CY; 2020; [cited 2021 Feb]. Available from: www.cms.gov
- Centers for Medicare & Medicaid Services. Medicare HO: CMS.gov. Physician fee schedule look-up tool. National 2020 payment amount by HCPCS code 2020; 2020; [cited 2020 Sep 23]. Available from: www.cms.gov
- Dalal AA, Guerin A, Mutebi A, et al. Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis. J Drug Assess. 2018;7(1):21–27.
- Graham J, Earnshaw S, Lim J, et al. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion mutations. J Clin Pathways. 2016;2(4):31–39.
- Agency for Healthcare and Research Quality. HCUPnet home page; 2021. Available from: https://hcupnet.ahrq.gov/#setup
- Centers for Medicare & Medicaid Services. Medicare HO: CMS.gov. Clinical laboratory fee schedule CY 2020. Q4 release 2020; [cited 2021 Jan]. Available from: www.cms.gov
- Gierman HJ, Pai N, Catasus C, et al. A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices. J Clin Oncol. 2020;38(15_suppl):e13668.
- Berchick ER, Barnett JC, Upton RD. Health insurance coverage in the United States: 2018. Current population reports 2019; 2020; [cited 2020 Jun 22]. Available from: https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-267.pdf
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence—SEER 9 Regs Research Data; 2019. Sub (1975–2017) 2020 [cited 2020 Jul 29]. Available from: https://canques.seer.cancer.gov/cgi-bin/cq_submit?dir=seer2017&db=1&rpt=TAB&sel=1∧0∧0∧107∧48∧0∧0∧1,22&x=Age%20at%20diagnosis∧1,22&dec=1,1,1&template=null